Will ‘Zemiglo’ handed to Daewoong change dynamics of the DPP-4 market?
As the domestic sales license of ‘Zemiglo,’ a domestic diabetes treatment which has been a hot potato since the beginning of this year, was passed to Daewoong Pharmaceutical, its future dynamic is expected to change.
According to the pharmaceutical industry on the 27th, LG Life Sciences establis...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
